COMMUNIQUÉS West-GlobeNewswire

ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer

27/09/2024 - 14:00

Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025 TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing [...]

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

27/09/2024 - 13:34

GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

27/09/2024 - 13:32

– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 [...]

Venus Concept Announces $15 million Debt-to-Equity Exchange Transaction

27/09/2024 - 13:30

Second Substantial Reduction of Existing Debt by Madryn Asset Management in 2024; the Company has reduced its debt balance by 54% year-to-date TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus [...]

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

27/09/2024 - 13:30

– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; [...]

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27/09/2024 - 13:00

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and [...]

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

27/09/2024 - 13:00

WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the [...]

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

27/09/2024 - 13:00

New patent expected to provide market exclusivity into 2036 Zembrace ® SymTouch ® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE [...]

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

27/09/2024 - 13:00

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 [...]

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO

27/09/2024 - 13:00

Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Cette approbation fait suite à celle obtenue dans l’Union européenne pour le traitement des adultes atteints de bronchopneumopathie [...]

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

27/09/2024 - 12:57

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help [...]

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

27/09/2024 - 12:05

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, [...]

Nexstim Receives Order for NBS System 5 in Finland

27/09/2024 - 09:00

Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System [...]

Information on the total number of voting rights and shares

27/09/2024 - 08:05

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024 , 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on [...]

Informations sur le nombre total de droits de vote et d'actions

27/09/2024 - 08:05

INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 27 septembre 2024, 8:05 CET / 2:05h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]

Publication relating to transparency notifications

27/09/2024 - 08:00

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024 , 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]

Publication relative à des notifications de transparence

27/09/2024 - 08:00

INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 27 septembre 2024 , 08:00h CET / 2:00h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

27/09/2024 - 05:26

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

27/09/2024 - 03:06

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and [...]